Cystic fibrosis mRNA candidate (MRT5005) fails to show benefit in Phase I/II clinical trial

MRT5005 was developed to treat the underlying cause of cystic fibrosis via the delivery of mRNA encoding fully functional CF transmembrane conductance regulator protein to cells within the lung via nebulisation. In the study, no improvement in lung function was noted.

Source:

Biospace Inc.